Down syndrome screening marker levels in women with a previous aneuploidy pregnancy

Prenatal Diagnosis

Volumn 25, Issue 1, 2005, Pages 47-50

  Cuckle, Howard S ^a,d   Spencer, K ^b,c   Nicolaides, K H ^c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b HAROLD WOOD HOSPITAL   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d Leeds Screening Centre   (United Kingdom)

Author keywords

Down syndrome; Markers; Previous aneuploidy; Screening

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTRIOL; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ALGORITHM; ANEUPLOIDY; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DOWN SYNDROME; EDWARDS SYNDROME; FAMILY HISTORY; FETUS; FETUS ECHOGRAPHY; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; PATAU SYNDROME; PRIORITY JOURNAL; UNITED KINGDOM;

ADULT; ALGORITHMS; ANEUPLOIDY; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; HUMANS; MASS SCREENING; PREGNANCY; PREGNANCY, HIGH-RISK; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; RISK ASSESSMENT;

EID: 13244262998     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.1082     Document Type: Article

References (24)

1. Arbuzova S. 1998. Why it is necessary to study the role of the mitochondrial genome in trisomy 21 pathogenesis? Downs Syndr Res Pract 5(3): 26-29.
2. Cuckle H, Arbuzova S 2004. Multianalyte maternal serum screening for chromosomal defects. In Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment, (5th edn), Milunsky Aubrey. (ed). Johns Hopkins University Press: Baltimore; 795-835.
3. Cuckle HS, Wald N, Stone R, Densem J, Haddow J, Knight G. 1998. Maternal serum thyroid antibodies in early pregnancy and fetal Down's syndrome. Prenat Diagn 8: 439-445.
4. Dar H, Merksamer R, Berdichevsky D, David M. 1996. Maternal serum markers levels in consecutive pregnancies: a possible genetic predisposition to abnormal levels. Am J Med Genet 61(2): 154-157.
5. De Graaf IM, Cuckle HS, Pajkrt E, Leschot NJ, Bleker OP, Van Lith JMM. 2000. Co-variables in first trimester maternal serum screening. Prenat Diagn 20(3): 186-189.
6. Holding S, Cuckle HS. 1994. Maternal serum screening for Downs syndrome taking account of the result in a previous pregnancy. Prenat Diagn 14: 321-322.
7. James SJ, Pogribna M, Pogribny IP, et al. 1999. Abnormal folate metabolism and mutation in the methylenetetrahydrofolate reductase gene may be maternal risk factors for Down syndrome. Am J Clin Nutr 70: 495-501.
8. Logghe H, Cuckle H, Sehmi I. 2003. Centre-specific ultrasound nuchal translucency medians needed for Down's syndrome screening. Prenat Diagn 23: 389-392.
9. Nasseri A, Mukherjee T, Grifo JA, Noyes N, Krey L, Copperman AB. 1999. Elevated day 3 serum follicle stimulating hormone and/or estradiol may predict fetal aneuploidy. Fertil Steril 71(4): 715-718.
10. Nicolaides KH, Sebire NJ, Snijders RJM. 1999. The 11-14 week scan. The diagnosis of fetal abnormalities. Parthenon: New York.
11. Nicolaides KH, Snijders RJ, Cuckle HS. 1998. Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat Diagn 18(5): 519-523.
12. Rudnicka AR, Wald NJ, Huttly W, Hackshaw AK. 2002. Influence of maternal smoking on the birth prevalence of Down syndrome and on second trimester screening performance. Prenat Diagn 22(10): 893-897.
13. Spencer K. 1997. Between-pregnancy biological variability of maternal serum alpha-fetoprotein and free beta hCG: implications for Down syndrome screening in subsequent pregnancies. Prenat Diagn 17(1): 39-45.
14. Spencer K. 1998. The influence of smoking on maternal serum AFP and free beta hCG levels and the impact on screening for Down's syndrome. Prenat Diagn 18: 225-234.
15. Spencer K. 1999. The influence of smoking on maternal serum PAPP-A and free beta hCG levels in the first trimester of pregnancy. Prenat Diagn 19(11): 1065-1066.
16. Spencer K. 2001. Between pregnancy biological variability of first trimester markers of Down syndrome: implications for screening in subsequent pregnancies. Prenat Diagn 21: 445-447.
17. Spencer K. 2002. Between pregnancy biological variability of first trimester markers of Down syndrome and the implications for screening in subsequent pregnancies: an issue revisited. Prenat Diagn 22: 874-876.
18. Spencer K, Bindra R, Cacho AM, Nicolaides KH. 2004. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. Prenat Diagn 24: 169-173.
19. Spencer K, Ong CYT, Liao AWJ, Nicolaides KH. 2000. The influence of parity and gravidity on first trimester markers of chromosomal abnormality. Prenat Diagn 20: 792-794.
20. Spencer K, Bindra R, Nix ABJ, Heath V, Nicolaides KH. 2003. Delta NT or NT MoM: Which is the most appropriate method for calculating patient specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynecol 22: 142-148.
21. van Montfrans JM, Dorland M, Oosterhuis GJ, van Vugt JM, Rekers-Mombarg LT, Lambalk CB. 1999. Increased concentrations of follicle-stimulating hormone in mothers of children with Down's syndrome. Lancet 353: 1853-1854.
22. Vergnes H, Grozdea J, Brisson-Lougarre A, et al. 1988. An enzymatic marker in mothers of trisomy 21 children: neutrophil alkaline phosphatase. Enzyme 39(3): 174-180.
23. Wald NJ, Kennard A, Hackshaw A, McGuire A. 1998. Antenatal screening for Down's syndrome. Health Technol Assess 2(1): i-iv, 1-112.
24. Wax JR, Lopes AM, Benn PA, Lerer T, Steinfeld JD, Ingardia CJ. 2000. Unexplained elevated midtrimester maternal serum levels of alpha fetoprotein, human chorionic gonadotropin, or low unconjugated estriol: recurrence risk and association with adverse perinatal outcome. J Matern Fetal Med 9(3): 161-164.